Atherosclerosis Drugs Global Market Report 2024

Description

Atherosclerosis drugs are medications employed for the management and treatment of atherosclerosis, a condition characterized by the accumulation of plaque in the arteries. The objectives of drug treatment for atherosclerosis include reducing plaque formation, slowing its progression, and addressing risk factors associated with the development of atherosclerosis.

The primary categories of atherosclerosis drugs encompass anti-platelet medications, fibric acid and omega-3 fatty acid derivatives, angiotensin-covering enzyme (ACE) inhibitors, diuretics, cholesterol-lowering medications, beta-blockers, calcium channel blockers, and other related medications. Antiplatelet medications are drugs that hinder the formation of blood clots by impeding the aggregation of platelets, which are small cell fragments in the blood. These drugs can be administered orally or through injections and are primarily dispensed through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others.

The atherosclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides atherosclerosis drugs market statistics, including atherosclerosis drugs industry global market size, regional shares, competitors with an atherosclerosis drugs market share, detailed atherosclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the atherosclerosis drugs industry. This atherosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The atherosclerosis drugs market size has grown steadily in recent years. It will grow from $48.72 billion in 2023 to $50.5 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The expansion observed in the historical period can be credited to efforts in cholesterol management, the control of blood pressure, the implementation of smoking cessation programs, research and development initiatives, and advancements in diagnostic technologies.

The atherosclerosis drugs market size is expected to see steady growth in the next few years. It will grow to $57.03 billion in 2028 at a compound annual growth rate (CAGR) of 3.1%. The anticipated growth in the forecast period can be ascribed to the emergence of new therapies, advancements in precision medicine, the focus on immunotherapy and inflammation, innovations in lipid management, and regulatory support. Key trends projected for the forecast period encompass the utilization of biologic therapies, the implementation of gene editing and gene therapy, the adoption of combination therapies, personalized treatment approaches, and the integration of telemedicine and remote monitoring.

The growth of the atherosclerosis drug market is expected to be propelled by the increasing prevalence of cardiovascular diseases. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, with atherosclerosis specifically involving the accumulation of fats, cholesterol, and other substances on artery walls. This condition, marked by plaque buildup inside the arteries, contributes to cardiovascular diseases such as coronary heart disease and stroke. Atherosclerosis drugs play a crucial role in treating cardiovascular diseases by reducing the risk of complications and managing underlying factors such as elevated cholesterol levels and the formation of blood clots. For example, a report published by The Office for National Statistics in March 2022 indicated that between 2020 and 2021, 19,440 to 20,061 people in the UK died due to heart attacks. Additionally, according to the Centers for Disease Control and Prevention in May 2023, 1 in 20 adults aged 20 and older in the US had cardiovascular diseases, with 695,000 people suffering from these conditions in 2021, and 375,476 deaths attributed to cardiovascular diseases that same year. Thus, the prevalence of cardiovascular diseases is expected to drive the atherosclerosis drug market.

The growth of the atherosclerosis drug market is anticipated to be fueled by the increasing aging population. The aging population refers to a demographic shift characterized by a significant rise in the proportion or number of individuals within a society who are considered elderly or senior citizens. Atherosclerosis drugs play a critical role in addressing elevated cardiovascular risks in the aging population, contributing to prevention, management, and treatment for overall well-being. For instance, as of June 2023, The United States Census Bureau reported a 0.2-year increase in the country's median age to 38.9 years in 2022, indicating a continued aging trend in the population. Consequently, the growing aging population is a driving force behind the growth of the atherosclerosis drug market.

Product innovation emerges as a prominent trend gaining momentum in the atherosclerosis drugs market. Major companies within the market are actively engaged in the development of innovative drugs and securing approvals as part of their strategy to maintain a strong market position. For example, in December 2021, Novartis AG, a pharmaceutical company based in Switzerland, obtained approval from the US Food and Drug Administration (FDA) for Leqvio (inclisiran), a groundbreaking siRNA designed to lower cholesterol and treat individuals with atherosclerotic cardiovascular disease. Administered through subcutaneous injection, this novel drug effectively reduces low-density lipoproteins (LDL) cholesterol levels in the bloodstream for adults with clinical atherosclerotic cardiovascular disease, offering a new treatment option for those unable to achieve their LDL cholesterol goals with existing therapies.

Major companies operating in the atherosclerosis drugs market are diversifying their product portfolios by introducing anti-inflammatory drugs to enhance market profitability. Anti-inflammatory drugs for atherosclerosis are specifically formulated to alleviate inflammation associated with the condition characterized by plaque buildup in arteries. For instance, AGEPHA Pharma, a European manufacturer of medical products, launched LODOCO. This drug, comprising colchicine in 0.5 mg tablets, received approval from the U.S. FDA as an innovative anti-inflammatory atheroprotective cardiovascular treatment. LODOCO has demonstrated efficacy in reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. Addressing residual inflammation, a critical factor in atherosclerotic cardiovascular disease (ASCVD), LODOCO can be used alone or in combination with cholesterol-lowering medications, marking a significant breakthrough in cardiovascular care.

In April 2023, Chiesi Farmaceutici S.p.A., an Italian pharmaceutical company, completed the acquisition of Amryt Pharma plc for an approximate sum of $1.25 billion. This strategic move aims to expand Chiesi Farmaceutici S.p.A.'s rare disease portfolio, gain access to Amryt's pipeline of developmental candidates, and establish a presence in the US market. Amryt Pharma plc, based in Ireland, specializes in the development of atherosclerosis drugs for the treatment of rare diseases, including atherosclerosis and generalized lipodystrophies.

Major companies operating in the atherosclerosis drugs market report are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc

North America was the largest region in the atherosclerosis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the atherosclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The atherosclerosis drugs market consists of sales of statins, rosuvastatin, atorvastatin, fibrates, bile acid sequestrants, nitrates, ezetimibe, and blood pressure medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atherosclerosis Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atherosclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atherosclerosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atherosclerosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Drug Class: Anti-Platelet Medications; Fibric Acid And Omega-3 Fatty Acid Derivatives; Angiotensin-Covering Enzyme (ACE) Inhibitors; Diuretics; Cholesterol Lowering Medication; Beta Blockers; Calcium Channel Blockers; Other Drug Classes
2) By Route Of Administration: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Other Distribution Channels
Companies Mentioned: Johnson And Johnson Private Limited; Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r14315

1. Executive Summary

2. Atherosclerosis Drugs Market Characteristics

3. Atherosclerosis Drugs Market Trends And Strategies

4. Atherosclerosis Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Atherosclerosis Drugs Market Size and Growth

5.1. Global Atherosclerosis Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Atherosclerosis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Atherosclerosis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Atherosclerosis Drugs Market Segmentation

6.1. Global Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Anti-Platelet Medications
Fibric Acid And Omega-3 Fatty Acid Derivatives
Angiotensin-Covering Enzyme (ACE) Inhibitors
Diuretics
Cholesterol Lowering Medication
Beta Blockers
Calcium Channel Blockers
Other Drug Classes
6.2. Global Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Injectable
6.3. Global Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Other Distribution Channels

7. Atherosclerosis Drugs Market Regional And Country Analysis

7.1. Global Atherosclerosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Atherosclerosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Atherosclerosis Drugs Market

8.1. Asia-Pacific Atherosclerosis Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Atherosclerosis Drugs Market

9.1. China Atherosclerosis Drugs Market Overview
9.2. China Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Atherosclerosis Drugs Market

10.1. India Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Atherosclerosis Drugs Market

11.1. Japan Atherosclerosis Drugs Market Overview
11.2. Japan Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Atherosclerosis Drugs Market

12.1. Australia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Atherosclerosis Drugs Market

13.1. Indonesia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Atherosclerosis Drugs Market

14.1. South Korea Atherosclerosis Drugs Market Overview
14.2. South Korea Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Atherosclerosis Drugs Market

15.1. Western Europe Atherosclerosis Drugs Market Overview
15.2. Western Europe Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Atherosclerosis Drugs Market

16.1. UK Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Atherosclerosis Drugs Market

17.1. Germany Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Atherosclerosis Drugs Market

18.1. France Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Atherosclerosis Drugs Market

19.1. Italy Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Atherosclerosis Drugs Market

20.1. Spain Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Atherosclerosis Drugs Market

21.1. Eastern Europe Atherosclerosis Drugs Market Overview
21.2. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Atherosclerosis Drugs Market

22.1. Russia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Atherosclerosis Drugs Market

23.1. North America Atherosclerosis Drugs Market Overview
23.2. North America Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Atherosclerosis Drugs Market

24.1. USA Atherosclerosis Drugs Market Overview
24.2. USA Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Atherosclerosis Drugs Market

25.1. Canada Atherosclerosis Drugs Market Overview
25.2. Canada Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Atherosclerosis Drugs Market

26.1. South America Atherosclerosis Drugs Market Overview
26.2. South America Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Atherosclerosis Drugs Market

27.1. Brazil Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Atherosclerosis Drugs Market

28.1. Middle East Atherosclerosis Drugs Market Overview
28.2. Middle East Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Atherosclerosis Drugs Market

29.1. Africa Atherosclerosis Drugs Market Overview
29.2. Africa Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Atherosclerosis Drugs Market Competitive Landscape And Company Profiles

30.1. Atherosclerosis Drugs Market Competitive Landscape
30.2. Atherosclerosis Drugs Market Company Profiles
- 30.2.1. Johnson And Johnson Private Limited
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Pfizer Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Bayer AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Atherosclerosis Drugs Market Other Major And Innovative Companies

31.1. Janssen Pharmaceuticals Inc.
31.2. Novartis AG
31.3. Merck And Co.Inc.
31.4. Sanofi S.A.
31.5. AstraZeneca plc
31.6. Abbott Laboratories
31.7. GSK plc.
31.8. Takeda Pharmaceutical Company Limited
31.9. Eli Lilly and Company
31.10. Gilead Sciences Inc.
31.11. Amgen Inc.
31.12. Novo Nordisk A/S
31.13. Boehringer Ingelheim International GmbH
31.14. Viatris Inc.
31.15. Teva Pharmaceutical Industries Ltd.

32. Global Atherosclerosis Drugs Market Competitive Benchmarking

33. Global Atherosclerosis Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Atherosclerosis Drugs Market

35. Atherosclerosis Drugs Market Future Outlook and Potential Analysis

35.1 Atherosclerosis Drugs Market In 2028 - Countries Offering Most New Opportunities
35.2 Atherosclerosis Drugs Market In 2028 - Segments Offering Most New Opportunities
35.3 Atherosclerosis Drugs Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer